个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共15条记录   Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma [作者：Dietrich, J; Wang, D; Batchelor, TT,期刊：Expert opinion on investigational drugs, 页码：1549-1557 , 文章类型： Editorial Material，,卷期：2009年18-10] Background: Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas. Objective: This review evaluates the preclinical an... Clofarabine: emerging role in leukemias [作者：Sampat, K; Kantarjian, H; Borthakur, G,期刊：Expert opinion on investigational drugs, 页码：1559-1564 , 文章类型： Editorial Material，,卷期：2009年18-10] Clofarabine is a second-generation purine nucleoside analogue. it works mainly by inhibiting ribonucleotide reductase and incorporating into DNA. Clofarabine has shown efficacy in selected pediatric leukemias. It has als... Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol) [作者：Fechner, J; Ihmsen, H; Jeleazcov, C; Schuttler, J,期刊：Expert opinion on investigational drugs, 页码：1565-1571 , 文章类型： Editorial Material，,卷期：2009年18-10] Background: Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvant... VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration [作者：Dixon, JA; Oliver, SCN; Olson, JL; Mandava, N,期刊：Expert opinion on investigational drugs, 页码：1573-1580 , 文章类型： Editorial Material，,卷期：2009年18-10] Background: Age-related macular degeneration (AMD) affects > 14 million individuals worldwide. Although 90% of patients with AMD have the dry form, neovascular AMD accounts for the vast majority of patients who develop l... Discontinued psychiatric drugs in 2008 [作者：Kirchhoff, VD; Nguyen, HTT; Soczynska, JK; Woldeyohannes, HO; McIntyre, RS,期刊：Expert opinion on investigational drugs, 页码：1431-1443 , 文章类型： Article，,卷期：2009年18-10] During the past several decades, neuropsychiatric agents have been one of the fastest growing classes of medicinal agents. This expansion is in part due to the increased recognition of the prevalence and burden of illnes... Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic [作者：Suckling, KE,期刊：Expert opinion on investigational drugs, 页码：1425-1430 , 文章类型： Editorial Material，,卷期：2009年18-10] Phase II results of the trials of two phospholipase A2 inhibitors which may be of value in the treatment of atherosclerosis and cardiovascular disease have been reported in the past year. Darapladib (GlaxoSmithKline) is ... Targeting IL-6 in the treatment of inflammatory and autoimmune diseases [作者：Ding, CH; Cicuttini, F; Li, J; Jones, G,期刊：Expert opinion on investigational drugs, 页码：1457-1466 , 文章类型： Review，,卷期：2009年18-10] Background: IL-6, a glycoprotein composed of 212 amino acids in human, has a wide range of biological activity, including regulation of immune response, support of hematopoiesis, generation of acute-phase reactions and i... Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? [作者：Petrelli, F; Cabiddu, M; Ghilardi, M; Barni, S,期刊：Expert opinion on investigational drugs, 页码：1467-1477 , 文章类型： Review，,卷期：2009年18-10] Approximately 10 - 15% of breast carcinomas (BCs) are known to be 'triple-negative (TN) receptor' (i.e., not expressing ER or PR and not exhibiting overexpression and/or gene amplification of HER2-neu). Triple-negative B... Investigational drugs targeting FLT3 for leukemia [作者：Ustun, C; DeRemer, DL; Jillella, AP; Bhalla, KN,期刊：Expert opinion on investigational drugs, 页码：1445-1456 , 文章类型： Review，,卷期：2009年18-10] FMS-like tyrosine kinase-3 (FLT3) is a member of the class III membrane receptor tyrosine kinase family and is important in survival, proliferation and differentiation of hematopoietic cells. FLT3 is mutated in similar t... Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease [作者：Seguin, RM; Ferrari, N,期刊：Expert opinion on investigational drugs, 页码：1505-1517 , 文章类型： Review，,卷期：2009年18-10] Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are disorders of the airways largely related to the presence of persistent inflammation. The approval of inhaled corticosteroid... Current progress in the pharmacological therapy of fibromyalgia [作者：Rao, SG,期刊：Expert opinion on investigational drugs, 页码：1479-1493 , 文章类型： Review，,卷期：2009年18-10] Fibromyalgia (FM) is a chronic musculoskeletal pain disorder often associated with fatigue, dyscognition, and sleep disturbances. Recent research advances highlight a critical role for aberrant central pain processing in... Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [作者：Rizzo, M; Rizvi, AA; Spinas, GA; Rini, GB; Berneis, K,期刊：Expert opinion on investigational drugs, 页码：1495-1503 , 文章类型： Review，,卷期：2009年18-10] Background: Type 2 diabetes is a chronic, progressive disease with a multifaceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally pro... Agomelatine, a melatonin agonist with antidepressant properties [作者：Dubovsky, SL; Warren, C,期刊：Expert opinion on investigational drugs, 页码：1533-1540 , 文章类型： Editorial Material，,卷期：2009年18-10] Agomelatine (beta-methyl-6-chloromelatonin), which is structurally homologous to melatonin, is a potent agonist of melatonin MT1 and MT2 receptors as well as an antagonist of serotonin 5-HT2c receptors. Agomelatine appea... AVE8062: a new combretastatin derivative vascular disrupting agent [作者：Delmonte, A; Sessa, C,期刊：Expert opinion on investigational drugs, 页码：1541-1548 , 文章类型： Editorial Material，,卷期：2009年18-10] Angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target. The tumor vascular network is the result of pro-angiogenic and inhibitory factors as well as of the i... Histamine H-3 and H-4 receptors as novel drug targets [作者：Tiligada, E; Zampeli, E; Sander, K; Stark, H,期刊：Expert opinion on investigational drugs, 页码：1519-1531 , 文章类型： Review，,卷期：2009年18-10] The identification of histamine H-3 (H3R) and H-4 (H4R) receptors some years ago revived interest in histamine research and exposed attractive perspectives for the potential therapeutic exploitation of these new drug tar...